{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T08:02:19Z","timestamp":1791619339929,"version":"4.3.4"},"reference-count":34,"publisher":"Tsinghua University Press","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.26599\/1671-5411.2023.02.007","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T03:41:43Z","timestamp":1679888503000},"page":"109-120","source":"Crossref","is-referenced-by-count":7,"title":["Different clinical characteristics and outcomes of hypertrophic cardiomyopathy with and without hypertension: seeking the truth"],"prefix":"10.26599","volume":"20","author":[{"given":"Yu","family":"ZHANG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hao","family":"LIU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Xin","family":"WU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"LIU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Zheng","family":"WANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Lu","family":"SUN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"JIANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"WANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian-Ming","family":"KANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Yi","family":"WU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Bao","family":"ZOU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"SONG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11138","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(12)60397-3","volume":"381","author":"MS Maron","year":"2013","unstructured":"MS Maron. Hypertrophic cardiomyopathy. 2013, 381: 242-255.","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(16)31321-6","volume":"389","author":"P Charron","year":"2017","unstructured":"P Charron. Hypertrophic obstructive cardiomyopathy. 2017, 389: 1253-1267.","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41569-021-00559-8","volume":"18","author":"GA Mensah","year":"2021","unstructured":"GA Mensah. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. 2021, 18: 785-802.","journal-title":"Nat Rev Cardiol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pcad.2019.11.009","volume":"63","author":"MH Stewart","year":"2020","unstructured":"MH Stewart. Left ventricular hypertrophy and hypertension. 2020, 63: 10-21.","journal-title":"Prog Cardiovasc Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41598-019-57230-z","volume":"10","author":"T Zhang","year":"2020","unstructured":"T Zhang. Retrospective analysis of clinical phenotype and prognosis of hypertrophic cardiomyopathy complicated with hypertension. 2020, 10: 349.","journal-title":"Sci Rep"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/0735-1097(89)90596-2","volume":"13","author":"BP Healy","year":"1989","unstructured":"BP Healy. Hypertensive hypertrophic cardiomyopathy or hypertrophic cardiomyopathy with hypertension? A study of 78 patients. 1989, 13: 580-584.","journal-title":"J Am Coll Cardiol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.21037\/acs.2017.07.07","volume":"6","author":"EJ Rowin","year":"2017","unstructured":"EJ Rowin. Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. 2017, 6: 353-363.","journal-title":"Ann Cardiothorac Surg"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"364","DOI":"10.21037\/acs.2017.07.08","volume":"6","author":"A Ralph-Edwards","year":"2017","unstructured":"A Ralph-Edwards. Isolated septal myectomy for hypertrophic obstructive cardiomyopathy: an update on the Toronto General Hospital experience. 2017, 6: 364-368.","journal-title":"Ann Cardiothorac Surg"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamacardio.2016.0252","volume":"1","author":"P Looser","year":"2016","unstructured":"P Looser. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003\u20132011. 2016, 1: 324-332.","journal-title":"JAMA Cardiol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1161\/CIRCULATIONAHA.120.050384","volume":"142","author":"Z Zhou","year":"2020","unstructured":"Z Zhou. East Asian-specific common variant in predisposes to hypertrophic cardiomyopathy. 2020, 142: 2086-2089.","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ejhf.144","volume":"16","author":"Y Zou","year":"2014","unstructured":"Y Zou. Malignant effects of multiple rare variants in sarcomere genes on the prognosis of patients with hypertrophic cardiomyopathy. 2014, 16: 950-957.","journal-title":"Eur J Heart Fail"},{"key":"ref12","first-page":"e533","volume":"142","author":"MA Burke","year":"2020","unstructured":"MA Burke. 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. 2020, 142: e533-e557.","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1161\/HYPERTENSIONAHA.119.13404","volume":"75","author":"W Wang","year":"2020","unstructured":"W Wang. Value of a machine learning approach for predicting clinical outcomes in young patients with hypertension. 2020, 75: 1271-1278.","journal-title":"Hypertension"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1136\/heartjnl-2020-317701","volume":"107","author":"S Wang","year":"2021","unstructured":"S Wang. N-terminal pro-brain natriuretic peptide and sudden cardiac death in hypertrophic cardiomyopathy. 2021, 107: 1576-1583.","journal-title":"Heart"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1148\/radiol.2021210914","volume":"302","author":"S Yu","year":"2022","unstructured":"S Yu. Patterns of replacement fibrosis in hypertrophic cardiomyopathy. 2022, 302: 298-306.","journal-title":"Radiology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12968-020-00610-6","volume":"22","author":"J Bremerich","year":"2020","unstructured":"J Bremerich. Standardized image interpretation and post-processing in cardiovascular magnetic resonance--2020 update: Society for Cardiovascular Magnetic Resonance (SCMR): board of trustees task force on standardized post-processing. 2020, 22: 19.","journal-title":"J Cardiovasc Magn Reson"},{"key":"ref17","first-page":"593","volume":"7","author":"MH Picard","year":"2014","unstructured":"MH Picard. Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging. 2014, 7: 593-604.","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.gie.2019.04.236","volume":"90","author":"JL Lund","year":"2019","unstructured":"JL Lund. Propensity score methods to control for confounding in observational cohort studies: a statistical primer and application to endoscopy research. 2019, 90: 360-369.","journal-title":"Gastrointest Endosc"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.amjcard.2020.01.045","volume":"125","author":"M Mimbrero","year":"2020","unstructured":"M Mimbrero. Basal ventricular septal hypertrophy in systemic hypertension. 2020, 125: 1339-1346.","journal-title":"Am J Cardiol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"MA Borger","year":"2014","unstructured":"MA Borger. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). 2014, 35: 2733-2779.","journal-title":"Eur Heart J"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1161\/01.CIR.0000150334.69355.00","volume":"110","author":"H Izawa","year":"2004","unstructured":"H Izawa. Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography. 2004, 110: 3808-3814.","journal-title":"Circulation"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/gim.2012.19","volume":"14","author":"M Varugheese","year":"2012","unstructured":"M Varugheese. Communicating new knowledge on previously reported genetic variants. 2012, 14: 713-719.","journal-title":"Genet Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/gim.2016.90","volume":"19","author":"JS Ware","year":"2017","unstructured":"JS Ware. Reassessment of Mendelian gene pathogenicity using 7855 cardiomyopathy cases and 60,706 reference samples. 2017, 19: 192-203.","journal-title":"Genet Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","volume":"138","author":"EA Ashley","year":"2018","unstructured":"EA Ashley. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). 2018, 138: 1387-1398.","journal-title":"Circulation"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41588-020-00764-0","volume":"53","author":"C Grace","year":"2021","unstructured":"C Grace. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. 2021, 53: 135-142.","journal-title":"Nat Genet"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"146S","DOI":"10.1093\/ajh\/7.10.146S","volume":"7","author":"MA Weber","year":"1994","unstructured":"MA Weber. Coronary heart disease and hypertension. 1994, 7: 146S-153S.","journal-title":"Am J Hypertens"},{"key":"ref27","first-page":"419","volume":"956","author":"C Matsumoto","year":"2017","unstructured":"C Matsumoto. Hypertension is a risk factor for several types of heart disease: review of prospective studies. 2017, 956: 419-426.","journal-title":"Adv Exp Med Biol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/ejhf.541","volume":"18","author":"R Coppini","year":"2016","unstructured":"R Coppini. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. 2016, 18: 1106-1118.","journal-title":"Eur J Heart Fail"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"W Spiering","year":"2018","unstructured":"W Spiering. 2018 ESC\/ESH guidelines for the management of arterial hypertension. 2018, 39: 3021-3104.","journal-title":"Eur Heart J"},{"key":"ref30","author":"","unstructured":"","journal-title":"null"},{"key":"ref31","author":"","unstructured":"","journal-title":"null"},{"key":"ref32","first-page":"S107","volume":"88","author":"SE Campbell","year":"1993","unstructured":"SE Campbell. Myocardial fibrosis: role of angiotensin II and aldosterone. 1993, 88: S107-S124.","journal-title":"Basic Res Cardiol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jchf.2014.08.003","volume":"3","author":"AL Cirino","year":"2015","unstructured":"AL Cirino. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. 2015, 3: 180-188.","journal-title":"JACC Heart Fail"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"117153","DOI":"10.1016\/j.lfs.2019.117153","volume":"244","author":"JM Parente","year":"2020","unstructured":"JM Parente. Verapamil decreases calpain-1 and matrix metalloproteinase-2 activities and improves hypertension-induced hypertrophic cardiac remodeling in rats. 2020, 244: 117153.","journal-title":"Life Sci"}],"container-title":["Journal of Geriatric Cardiology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T03:42:05Z","timestamp":1679888525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciopen.com\/article\/10.26599\/1671-5411.2023.02.007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"URL":"https:\/\/doi.org\/10.26599\/1671-5411.2023.02.007","relation":{},"ISSN":["1671-5411"],"issn-type":[{"value":"1671-5411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}